Peter Becker’s Post

🚀 We're thrilled to be speaking at #DPharm2024 on how our partnership with Eli Lilly is transforming vendor management in clinical trials. Join Kenneth Olovich, Executive Director of Sourcing, Procurement and Finance, Chorus Division, Eli Lilly and Patricia Leuchten, Founder and CEO of Diligent Pharma, as we discuss an innovative approach to vendor management that reduces the inefficiencies inherent in current processes and helps speed-up clinical trial start-up times for the benefit of patients. Don't miss our session, "Diligent Pharma and Eli Lilly: Accelerating Trial Startup and Reducing Vendor Management Burden Through a Centralized Model," and learn how the Diligent centralized quality and risk management platform is driving smarter, data-driven decision-making in clinical trials. 📅 Tuesday, September 17, 2024, 4:10 PM at DPHARM: Disruptive Innovations to Modernize Clinical Research 💬 We look forward to connecting with you at the show! #ClinicalTrials #VendorManagement #PharmaInnovation #RegulatoryCompliance #PatientFirst #DiligentPharma #EliLilly

Super pleased to share our next Healthcare and Life Sciences M&A Insights paper. If you would like to know more about the Market Access M&A market after reading this paper, or have any other questions on the wider Pharmaceutical Services sector, please do get in touch - claire.edwards@alvarezandmarsal.com . We would be delighted to discuss this report with you, including any implications these current and longer-term market themes may have on your business and overall shareholder objectives. #marketaccess #pharmaservices #mergersandacquisitions #alvarezandmarsal #alvarezandmarsalcorporatefinance

We are pleased to announce that the next paper in our series of Healthcare and Life Sciences M&A Insights reports is out now! 💊 In our latest report of the series, we explore how the increasing complexity of Market Access has prompted more pharmaceutical companies to outsource their commercialisation services to specialised providers, revealing a positive M&A outlook. Combined with a new UK government that has promised funding stability for continued R&D and a commitment to strengthening underlying infrastructure, sector optimism has increased and the demand for acquisitions within Market Access Services continues to gain strong momentum.  We explore these market themes, the broader M&A landscape, key transactions shaping the sector and a wider sector and political outlook within our report. If you would like to know more about the Market Access M&A market after reading this paper, or have any other questions on the wider Pharmaceutical Services sector, please do get in touch - asultan@alvarezandmarsal.com . We would be delighted to discuss this report with you, including any implications these current and longer-term market themes may have on your business and overall shareholder objectives. #marketaccess #pharmaservices #mergersandacquisitions #alvarezandmarsal #alvarezandmarsalcorporatefinance Claire Edwards Chris Savidge Lara Tentori Rob Sher, ACA Ananaya Gupta Steven Young Priyesh Talati Megha Chalke Bridget Phillip

While the Big Pharma M&A deals post-COVID are considerably less than the activity we witnessed pre-COVID, that does not make them any less significant in terms of what they will mean for the industry going forward, especially those that played a big part during COVID. Read all about it in The Weekly Brief https://lnkd.in/eCbZrP9. #M&As #Partnerships #BigPharma #PharmaCircle

NEWS OF THE DAY! Sanofi's Consumer Health Unit Sparks Private Equity Interest: A $20 Billion Opportunity   1.     Sanofi (SNY) ADRs rose by 3.2% following reports of interest from various private equity firms in the pharmaceutical giant's consumer health unit. 2.     Avent International, Blackstone(BX), Bain Capital, CVC Capital Partners, EQT Group AB, and KKR. (KKR) are among the large buyout firms expressing interest in the consumer health business. 3.     The consumer health unit of Sanofi sells over-the-counter products such as Phytoxil cough syrups and Icy Hot pain relief gels and may be valued at approximately $20 billion in any potential transaction. 4.     Sanofi is open to selling the consumer health unit if it receives the right valuation, as indicated by advisers to the company. 5.     Bloomberg previously reported in November that Sanofi was preparing for a separation of its consumer health business, attracting interest from major private equity firms. 6.     Sanofi announced plans in late October to spin off its consumer healthcare business. =>Please follow Finplate and stay updated with the latest #mergersandacquisitions news. Thanks in advance. To read the news in detail, click below: https://lnkd.in/g7XXRn2h

In a new report focusing on portfolio strategy and business development, my colleagues Cody Powers and Josh Hattem share data around #pharma launches and approvals, what’s driving industry growth, why clinical trials continue to decline and more.  https://lnkd.in/edghcwTS

This is a lively discussion on private equity, public companies, boards, and working in healthcare with John Chiminski, who has done them all. The former CEO of Catalent Pharma Solutions, John has definitive views on these and other topics. Watch the interview here: https://lnkd.in/eYBUGjbW #leadershipdevelopment

Thrilled to explore the strategies that drive top-notch sales teams in the pharmaceutical realm! Companies that prioritize ongoing training, equip reps with cutting-edge technology, and foster a culture of collaboration consistently outperform. By investing in skills development, providing robust resources, and encouraging continuous learning, we empower our teams to excel in delivering value to healthcare professionals and ultimately, improve patient outcomes. Here's to building sales excellence in pharma! #PharmaSales #SalesEffectiveness #TeamEmpowerment

The market research firm PitchBook reports private equity-backed healthcare deals have continued to decline, dropping 16.5% in the second quarter of this year. The market has been on a downward trend since 2021, but may be poised for a turnaround according to Healthcare Dive. "Bankers have noted their acquisition pipelines are filling up, and sellers’ price expectations are beginning to decrease — signaling that a gradual increase in dealmaking could be coming," writes reporter Emily Olsen. PitchBook's Healthcare Services Report claims that the acceleration in private equity deals will likely be focused on pharmaceutical services, healthcare information technology and other non-physician practice management firms. You can read full coverage of the report at: https://lnkd.in/e3GZWNwx #HealthcareDeals #PitchBook #PrivateEquityTrends

#Pharma services businesses need to be global to succeed, and North America is a crucial market, according to Dr Charles Woler, a #healthcare professional with over 30 years’ experience in multinational as well as smaller earlier-stage businesses and part of Inflexion’s Healthcare Advisory Board. North America offers enormous growth opportunities as it is the largest market worldwide with a single language and culture, making it fundamentally different from Europe. However, its sheer size and complexity mean that to capture a significant market share, a physical presence is essential. While anyone can sell into the US, truly succeeding is a different matter. Discover Charles' strategies for thriving in the US market and how private equity can support mid-market pharmaceutical businesses in their expansion efforts. 🌎 ➡️ https://lnkd.in/eTsrzyUj #BackingAmbition #AcceleratingGrowth